Evidence map›Paper›PMID 37767302›Full record

ArticleGE Portuguese journal of gastroenterology2023

Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal.

Fernando Magro, Francisco Portela, Paula Lago, Cristina Chagas, Francisco Moreira, Fábio Pereira, Bernardo Rodrigues, Hugo Pedrosa, Luis Correia

Abstract read
In one paragraph

Article in GE Portuguese journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fernando MagroGastroenterology Department, Centro Hospitalar São João, Porto, Portugal.
Francisco PortelaIBD Portuguese Group (GEDII), Porto, Portugal.
Paula LagoIBD Portuguese Group (GEDII), Porto, Portugal.
Cristina ChagasIBD Portuguese Group (GEDII), Porto, Portugal.
Francisco MoreiraIQVIA Solutions Portugal, Lisbon, Portugal.
Fábio PereiraIQVIA Solutions Portugal, Lisbon, Portugal.
Bernardo RodriguesJanssen Portugal, Lisbon, Portugal.
Hugo PedrosaIQVIA Solutions Portugal, Lisbon, Portugal.
Luis CorreiaIBD Portuguese Group (GEDII), Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Inflammatory bowel diseases' (IBD) increasing incidence and prevalence place a heavy health and economic burden on society. Objectives: This study assesses the burden and cost of IBD in Portugal to support the definition of health policies, resource allocation, and patient care. Methods: The burden of disease was expressed using disability-adjusted life years (DALY). Costs were estimated considering the societal perspective, using a prevalence-based model and prices established by law. An expert panel composed of 5 expert Portuguese gastroenterologists and a patient-reported study were conducted to support the cost analysis and fill in information gaps. Results: In Portugal, with a prevalence of 24,069 IBD patients and an incidence of 15/100,000, the burden of disease was estimated at 6,067 DALYs: 507 resulting from premature deaths and 5,560 from disability. Total cost was estimated at EUR 146 million per year, with direct costs representing 59%. Average yearly cost per IBD patient is EUR 6,075, where 60% is related to Crohn's disease and 40% to ulcerative colitis (UC). Conclusion: This study estimates the annual health burden and cost of IBD in Portugal, thus generating information with the intent to raise awareness of the need to advance health policies as well as better clinical and economic decisions in this pathology.

Indexed as

Burden of diseaseCost of illnessCrohn's diseaseInflammatory bowel diseaseUlcerative colitis

Identifiers

PMID37767302
PMCPMC10521318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.